Clinical Trials
97 trialsPRECIOUS
Japan Breast Cancer Research Group
T-VEC With Chemotherapy or Endocrine Therapy in Treating Participants With HER2- Negative Breast Cancer
University of California, San Francisco
A Study of LY2880070 in Participants With Advanced or Metastatic Cancer
Esperas Pharma Inc.
ADAPT
West German Study Group
A Phase 1/2 Study of CYT-0851 in B-Cell Malignancies and Advanced Solid Tumors
Cyteir Therapeutics, Inc.
IVY
Eli Lilly and Company
TROPiCS-02
Gilead Sciences
RIGHT Choice
Novartis
PRESERVE 2
G1 Therapeutics, Inc.
Study of Oral Vinorelbine Plus Capecitabine Versus Taxane-gemcitabine Combinations as 1st Line Chemotherapy in Metastatic Breast Cancer
Pierre Fabre Medicament
Mirvetuximab Soravtansine and Gemcitabine Hydrochloride in Treating Patients With FRalpha-Positive Recurrent Ovarian, Primary Peritoneal, Fallopian Tube, Endometrial, or Triple Negative Breast Cancer
City of Hope Medical Center
A Study of SY 5609, a Selective CDK7 Inhibitor, in Advanced Solid Tumors
Syros Pharmaceuticals
Gemcitabine Hydrochloride and Genistein in Treating Women With Stage IV Breast Cancer
Barbara Ann Karmanos Cancer Institute
Vinorelbine Versus Gemcitabine Plus Vinorelbine in Metastatic Breast Cancer Patients
Spanish Breast Cancer Research Group
ATTAIN
Nektar Therapeutics
Gemcitabine, Doxorubicin and Paclitaxel (GAT) as Neoadjuvant Treatment of Breast Cancer Patients
Spanish Breast Cancer Research Group
Type I-Polarized Autologous Dendritic Cell Vaccine With Tumor Blood Vessel Antigen-Derived Peptides in Metastatic Breast Cancer Patients
Case Comprehensive Cancer Center
ASCENT
Gilead Sciences
TNBC
Fudan University
Neo-adjuvant Gemcitabine, Epirubicin, ABI-007 (GEA) in Locally Advanced or Inflammatory Breast Cancer
SCRI Development Innovations, LLC
Weekly Gemcitabine, Epirubicin, and Docetaxel in Locally Advanced or Inflammatory Breast Cancer
SCRI Development Innovations, LLC
Phase I/IIa Trial of Gemcitabine Plus Trastuzumab and Pertuzumab in Previously Treated Metastatic HER2+ Breast Cancer
H. Lee Moffitt Cancer Center and Research Institute
SYSUCC-002
Sun Yat-sen University
EG_PG
Asan Medical Center
Study to Evaluate the Safety and Tolerability of Andecaliximab as Monotherapy and in Combination With Chemotherapy in Participants With Advanced Solid Tumors
Gilead Sciences
Association of Survival With Maintenance Therapy in Patients With Metastatic Breast Cancer After First-line Chemotherapy
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
A Drug-Interaction Study of Necitumumab (IMC-11F8) in Combination With Gemcitabine-Cisplatin
Eli Lilly and Company
Docetaxel vs. Docetaxel-Gemcitabine in Breast Cancer
Eli Lilly and Company
Safety Study of Nivolumab With Nab-Paclitaxel Plus or Minus Gemcitabine in Pancreatic Cancer, Nab-Paclitaxel / Carboplatin in Stage IIIB/IV Non-Small Cell Lung Cancer or Nab-Paclitaxel in Recurrent Metastatic Breast Cancer
Celgene
tnAcity
Celgene
Phase 2 Study of Gemzar, Taxol & Avastin Combination as 1st Line Treatment for Metastatic Breast Cancer
Stanford University
Gemcitabine and Liposomal Doxorubicin in Treating Women With Metastatic Breast Cancer
M.D. Anderson Cancer Center
Carboplatin, Gemcitabine Hydrochloride, and Mifepristone in Treating Patients With Advanced Breast Cancer or Recurrent or Persistent Ovarian Epithelial, Fallopian Tube, or Primary Peritoneal Cancer
University of Chicago
Combination Chemotherapy in Treating Women Who Have Undergone Surgery for Node-Positive Breast Cancer
NSABP Foundation Inc
Gemcitabine/ Trastuzumab and Gemcitabine/ Cisplatin/ Trastuzumab in Patients With Metastatic Breast Cancer
Ohio State University Comprehensive Cancer Center
Bortezomib and Gemcitabine in Treating Older Patients With Advanced Solid Tumors
Masonic Cancer Center, University of Minnesota
Abraxane, Avastin, and Gemcitabine as First-Line Therapy for Patients With Metastatic Breast Cancer
University of Miami
Maintenance Versus Observation After 6 Cycles of Gemcitabine Plus Paclitaxel in Pts With Advanced Breast Cancer
Samsung Medical Center
Irinotecan Plus Gemcitabine in Treating Patients With Unresectable or Metastatic Solid Tumors
Northwestern University
Paclitaxel Albumin-Stabilized Nanoparticle Formulation, Gemcitabine, and Bevacizumab in Treating Patients With Metastatic Breast Cancer
Alliance for Clinical Trials in Oncology
A Study of Biweekly Gemcitabine, Paclitaxel, and Avastin in Patients With Metastatic Breast Cancer
Barbara Ann Karmanos Cancer Institute
LY231514 Plus Gemcitabine in Treating Women With Metastatic Breast Cancer
Alliance for Clinical Trials in Oncology
Erlotinib and Gemcitabine in Treating Patients With Metastatic Breast Cancer Previously Treated With An Anthracycline and/or a Taxane
Alliance for Clinical Trials in Oncology
A Study of ALT-836 in Combination With Gemcitabine for Locally Advanced or Metastatic Solid Tumors
Altor BioScience
Gemcitabine and Cisplatin in Treating Patients With Metastatic Breast Cancer
Alliance for Clinical Trials in Oncology
A Study of Bevacizumab in Combination With Gemcitabine and Carboplatin in Participants With Triple Negative Metastatic Breast Cancer
Hoffmann-La Roche
A Phase II Study of Abraxane Gemcitabine Combination in Patients With Metastatic Breast Cancer
Fudan University
Panitumumab, Gemcitabine and Carboplatin in Triple-Negative Metastatic Breast Cancer
SCRI Development Innovations, LLC
TNBC
Fudan University
Tipifarnib and Gemcitabine Hydrochloride in Treating Women With Metastatic Breast Cancer
National Cancer Institute (NCI)